VEZT

Across TCGA pan-cancer cohorts, VEZT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VEZT data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher VEZT mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VEZT expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where VEZT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.339	1.000	.003	40	view →
LUAD	DFS	Quartile	All	0.606	1.000	.006	13	view →
PDAC	DFS	Quartile	All	0.662	0.856	.005	7	view →
HNSC	OS	Median	IV	0.868	0.621	.006	7	view →
LSCC	DFS	Tertile	All	1.000	0.533	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

VEZT–CCRCC (OS)

Open the CCRCC breakdown →